The linked FDA records identify Roche Molecular Systems, Inc. as the applicant on ten linked premarket approval filings, all under the PMA pathway, with six approval decisions and four 30-day notices. The records cover three named tests: cobas® KRAS Mutation Test, cobas® BRAF V600 Mutation Test and cobas® HPV. The KRAS and BRAF records carry the generic name Somatic Gene Mutation Detection System and product code OWD; the HPV record carries the generic name Kit, DNA Detection, Human Papillomavirus and product code MAQ. The KRAS test is described by Roche Diagnostics as a real-time PCR test for somatic mutations in codons 12, 13 and 61 of the KRAS gene in DNA derived from formalin-fixed paraffin-embedded human colorectal cancer tumor tissue, for use with the cobas® 4800 System. [1][2][4][8][10]
Documented products and filing scope
The cobas® KRAS Mutation Test appears under PMA P140023, the cobas® BRAF V600 Mutation Test under P110020 and cobas® HPV under P100020. The KRAS and BRAF filings list the applicant address as 4300 Hacienda Drive, Pleasanton, CA, and the advisory committee as Pathology; the HPV filing lists Microbiology. The KRAS summary of safety and effectiveness data names Roche Molecular Systems, Inc. (RMS) as applicant and gives a date of notice of approval of May 7, 2015 for P140023. [1][2][4][8]
The cobas® KRAS Mutation Test is described by Roche Diagnostics as a real-time PCR test for detection of somatic mutations in codons 12, 13 and 61 of the KRAS gene in DNA derived from formalin-fixed paraffin-embedded human colorectal cancer tumor tissue, for use with the cobas® 4800 System. The linked FDA records for the BRAF V600 and HPV tests give generic names and product codes without describing their assay technology. [4][10]
Labeling supplements decided in November 2026
Two labeling supplements were approved on November 4, 2026: P140023/S034 for the Roche cobas® KRAS Mutation Test and P110020/S046 for the Roche cobas® BRAF V600 Mutation Test. Both were received October 6, 2026, classified as Special (Immediate Track) supplements with the reason Labeling Change - Indications/instructions/shelf life/tradename, and neither carried an expedited review flag. [1][2]
The approval statements for both supplements describe updates to hazard information on product labeling for the cobas® DNA Sample Preparation Kit, a component of the cobas® KRAS Mutation Test, cobas® BRAF V600 Mutation Test and cobas® EFGR Mutation Test, v2.0. The component is named in the filing text; the linked FDA records do not describe the hazard content or the revised label language. [1][2]
Process-change notices decided in October 2026
Three 30-day notices were decided on October 27, 2026, each received September 30, 2026, with the stated purpose of changing the manufacturing process for oligonucleotides. They are P140023/S033 for the cobas® KRAS Mutation Test, P110020/S045 for the cobas® BRAF V600 Mutation Test and P100020/S066 for cobas® HPV. All three are recorded as Process Change - Manufacturer/Sterilizer/Packager/Supplier notices without an expedited review flag. [3][4][5]
How to read the collection
The ten linked records and the six approval and four 30-day decision counts describe the supplied filing snapshot as of November 20, 2026; they are not measures of total company sales, total portfolio or safety performance. The five-record sample shows two approvals and three 30-day notices, a smaller denominator than the full collection. The records do not establish a parent company, brand ownership, headquarters or commercial availability, and the Pleasanton address is the applicant address in the filings. [1][2][3][4][5]







